APA (7th ed.) Citation

Simon, M., Liu, Q., Flaherty, L., Lum, L. G., Thakur, A., Deol, A., . . . Giroux, M. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Simon, Michael, et al. Phase II Clinical Trial Using Anti-CD3 × Anti-HER2 Bispecific Antibody Armed Activated T Cells (HER2 BATs) Consolidation Therapy for HER2 Negative (0–2+) Metastatic Breast Cancer. BMJ Publishing Group.

MLA (9th ed.) Citation

Simon, Michael, et al. Phase II Clinical Trial Using Anti-CD3 × Anti-HER2 Bispecific Antibody Armed Activated T Cells (HER2 BATs) Consolidation Therapy for HER2 Negative (0–2+) Metastatic Breast Cancer. BMJ Publishing Group.